Jardine Matheson Holdings Limited

All figures from JMH Annual Report 2025, Five-Year Summary, unless otherwise stated. FY2024 figures re-presented in AR 2025 for the reclassification of non-strategic business into non-trading items; FY2022 and FY2023 marked as restated in the summary.

Income statement

Margins and payout are analyst calculations from the reported figures. Revenue CAGR FY2021–FY2025: -1.2% p.a. (analyst calculation: (34,217/35,862)^(1/4) − 1). Underlying profit CAGR FY2021–FY2025: +2.7% p.a. Underlying EPS CAGR FY2021–FY2025: +4.3% p.a. (helped by the 2021 Jardine Strategic share cancellation).

FY2025 vs FY2024 detail (AR 2025, Consolidated Profit and Loss Account):

FY2025 total tax charge was US$910m (underlying US$797m), and the Group recognised US$798m of impairment losses on associates and joint ventures within non-trading items (H1 2026 results, FY2025 comparative column). Share of underlying results of associates and joint ventures was US$1,094m in FY2025, broadly flat on FY2024 (AR 2025 CFO statement).

Gross profit and EBITDA. JMH does not present gross profit or EBITDA on the face of its consolidated income statement for the full years in the summary; the five-year summary omits them. From the H1 interim notes, cost of sales was US$11,570m in H1 2026 and US$12,339m in H1 2025, implying gross profit of US$4,354m (27.3% margin) and US$4,739m (27.7%) respectively (analyst calculation). Full-year FY2021–FY2025 gross profit, operating income on a consistent basis, and EBITDA are not publicly disclosed in the summary data verified here. S&P Global Ratings (April 2025 research) estimated the Group's debt-to-EBITDA at 2.2x for 2024, falling to about 2.0x in 2025 and 1.8x in 2026, on its own adjusted basis.

Balance sheet

Debt structure at 31 December 2025 (AR 2025 / H1 2026 balance sheet comparative):

Net borrowings excluding Astra's financial services companies increased by US$906m in H1 2026, and gearing (net debt to total equity) stood at about 7% at 30 June 2026 (Quartr summary of H1 2026 results); Group liquidity headroom was US$12.7bn. JMH parent was in a net cash position of US$379m at 30 June 2026 versus US$41m at 31 December 2025 (H1 2026 results).

Working capital (current assets less current liabilities, analyst calculation): US$8,147m at 31 December 2025; US$4,011m at 30 June 2026 (the decline reflects completion of held-for-sale disposals, the Mandarin Oriental privatisation and higher current borrowings).

Cash flow

FY2025 cash flow detail (H1 2026 results, FY2025 comparative column):

FY2025 dividends declared and accounted for by the Company totalled US$658m, of which US$197m was settled in scrip (FY2025 statement of changes in equity).

Parent free cash flow (recurring dividend income less corporate costs and net financing charges) rose 21% to US$709m in H1 2026 from US$585m in H1 2025.

Ratios

All ratios are analyst calculations from the five-year summary. ROIC, interest coverage on a consistent five-year basis, net debt/EBITDA (company basis) and cash conversion cycle are not publicly disclosed by the Company in the data verified. Point calculations: underlying operating profit / underlying financing charges = 5.0x (FY2024) and 5.3x (FY2025); current ratio = 1.53x (31 December 2025) and 1.25x (30 June 2026).

Interim 2026 snapshot

Source: H1 2026 results. "Adjusted" removes business disposals and the Zhongsheng reclassification.

Commentary on trends, inflections and drivers

Revenue has drifted down for three consecutive years (FY2022 peak US$37.5bn to FY2025 US$34.2bn, and a further 7% decline in H1 2026). The drivers are mostly deliberate or exogenous rather than franchise erosion: DFI's exits from Yonghui, Robinsons Retail, Hero and Singapore Food remove consolidated or proportionate revenue; Astra's four-wheeler market and coal-linked heavy equipment cycle have softened; the rupiah has weakened against the US dollar (Astra's H1 2026 profit fell 7% in rupiah but 12% in dollars); and HKL's build-to-sell wind-down has shifted residential revenue into non-trading items. Revenue is therefore a poor gauge of value creation at Jardines and is not targeted by management.

Underlying profit has been resilient and is now growing, rising 11% in FY2025 to a five-year high of US$1,681m and 9% (adjusted) in H1 2026. The quality of that growth has improved: DFI (+35% in 2025), Jardine Pacific and JC&C drove gains, corporate costs fell sharply with the parent headcount cut, and financing costs declined as net debt collapsed from US$7.3bn to US$2.7bn in FY2025. Management upgraded FY2026 underlying EPS guidance on 13 October 2026 to US$5.50–5.65, which implies 3–6% growth over adjusted 2025.

Reported earnings have been extremely volatile (US$1,881m in FY2021 to a US$468m loss in FY2024 and back to US$1,109m in FY2025), almost entirely because of non-cash revaluation of Hongkong Land's investment properties (US$2.2bn fair value loss in FY2024) and impairments of associates (US$798m in FY2025). H1 2026 reported profit was depressed by US$557m of fair value losses on other investments, primarily Zhongsheng, partly offset by US$571m of investment property gains.

The balance sheet inflected sharply in FY2025. Net borrowings excluding financial services fell 63% to US$2.7bn on US$4.8bn of capital recycled, giving the Group capacity to fund the I-MED acquisition (US$2.4bn), the Mandarin Oriental privatisation and buybacks. Gearing is expected to rise modestly on I-MED completion but from a very low base (about 7% at June 2026).

Returns remain the core weakness. Underlying ROE of 5–6% on book equity is below the Group's own >11% new-investment hurdle and explains the persistent discount to NAV (shares at c.US$58 vs NAV per share of c.US$97). The strategic reset is fundamentally an attempt to lift this return on capital through recycling sub-7% assets into higher-return platforms and buying back stock below NAV.

Management guidance

• FY2026 underlying EPS of US$5.50–5.65 (raised 13 October 2026 from US$5.33), +3% to +6% versus adjusted 2025.

• FY2026 DPS of at least US$2.47 (+5%).

• H2 2026 priorities: TSR, portfolio cash flow, simplification, I-MED integration, "significant progress" on further capital recycling.

• Astra: continued Indonesian macro headwinds for the rest of 2026, modest H2 improvement and stronger Mining Solutions & Heavy Equipment performance with Martabe back in operation.

• HKL: full-year underlying profit growth broadly in line with H1 growth.

• DFI: FY2026 underlying net profit guidance raised to US$285–305m.

Consensus growth expectations

Consensus (August 2026) expected FY2026 revenue to decline about 2% to US$32.3bn, with a meaningful EPS rebound; revenue is expected to keep shrinking near term, albeit more slowly. The October guidance upgrade suggests upward revisions are likely.

Bull case

1. NAV discount compression through self-help. At c.0.6x NAV per share and c.10x underlying earnings, every dollar recycled from sub-7% assets into buybacks or >11% acquisitions mechanically lifts NAV per share and ROE; US$4.8bn recycled in FY2025 and US$1.5bn in H1 2026 shows the programme is real.

2. Earnings momentum with upgrade cycle. Underlying profit hit a five-year high in FY2025, guidance was raised in October 2026, and I-MED (12% EBITDA CAGR) plus Gammon add structurally higher-growth earnings, while parent FCF grew 21% in H1 2026.

3. Astra as a coiled spring. Astra's contribution is depressed by a cyclical Indonesian trough and rupiah weakness; its new returns-focused roadmap, US$560m of new Astra/UT buybacks and Martabe's restart could drive both earnings recovery and a re-rating of the Group's largest asset.

Bear case

1. Structural low returns. Underlying ROE has been stuck at 5–6% for five years; much of the portfolio (Hong Kong office, mature retail, Japanese-brand autos) faces secular pressure, and recycling at scale takes years given the asset base management itself acknowledges.

2. Indonesia concentration and EV disruption. Nearly half of segment profit comes from Astra, whose core four-wheeler franchise faces Chinese EV competition and whose mining businesses are coal-exposed and politically sensitive.

3. Acquisition and governance risk. The pivot toward M&A (I-MED at c.11.5x EBITDA in a new country and sector) introduces integration and overpayment risk, while family control and an executive chairman may limit the market's willingness to close the discount; the Jardine Strategic appraisal could produce an unexpected cash liability.

Catalysts and monitorables (next 12 months)

Analyst verdict

Jardine Matheson in October 2026 is a company mid-way through the most consequential strategic reset in its modern history, and the evidence suggests the reset is genuine rather than cosmetic. In under two years the Group has privatised Mandarin Oriental, exited a string of minority holdings, cut parent headcount by nearly half, reduced net borrowings by almost two-thirds, set its first-ever quantified mid-term targets, hired a private-equity CEO, and executed its first major control acquisition in years. Underlying earnings reached a five-year high in 2025 and guidance was raised in October 2026. The balance sheet, with gearing around 7% and US$12.7bn of liquidity headroom, can absorb I-MED and continued buybacks without strain.

Yet the market's verdict remains sceptical, and with reason. The shares trade at roughly 0.6x NAV per share and around 10x underlying earnings because the Group's return on equity has never escaped the 5–6% range, because almost half of profits depend on an Indonesian conglomerate facing cyclical and structural pressure, and because family control has historically constrained minority-friendly outcomes. The 5Y TSR of 4.4% p.a. sits far below the 9% target management has chosen to be measured against.

Our synthesis is that Jardines has the assets, the balance sheet and now the stated discipline to compound NAV per share faster than at any time in the past decade, and buybacks below NAV are an unusually reliable value lever. The investment debate over the next 12–24 months will hinge on three tests: whether I-MED integrates smoothly and delivers on its growth record, whether Astra's returns-focused roadmap stabilises the Group's largest earnings stream, and whether capital recycling continues at the pace of 2025. Success on all three would justify meaningful discount narrowing; failure on Astra in particular would leave the stock a cheap but stagnant holding company.